Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Eisai disclosed in its fiscal 1Q13 earnings that Humira adalimumab was approved in Japan
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury